Nirvana Life Sciences
Is focused on developing medical.
Market cap
€2.4m
Enterprise valuation
€2m (Public information from Sep 2024)
Share price
CAD0.075 NIRV.CN
Vancouver British Columbia (HQ)
Financials
Estimates*
CAD | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|
EBITDA | (<1m) | (<1m) | 3.4m | (1.2m) |
Profit | (<1m) | (<1m) | (5.7m) | (1.5m) |
EV / EBITDA | - | - | 1.2x | -0.9x |
R&D budget | - | - | <1m | <1m |
Date | Investors | Amount | Round |
---|---|---|---|
$450k | Early VC | ||
N/A | N/A | IPO | |
* | N/A | Acquisition | |
Total Funding | €409k |